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ABSTRACT Cells that actively transcribe HIV-1 have been defined as the “active
viral reservoir” in HIV-infected individuals. However, important technical limita-
tions have precluded the characterization of this specific viral reservoir during
both treated and untreated HIV-1 infections. Here, we used a novel single-cell
RNA fluorescence in situ hybridization-flow cytometry (FISH-flow) assay that requires
only 15 million unfractionated peripheral blood mononuclear cells (PBMCs) to charac-
terize the specific cell subpopulations that transcribe HIV RNA in different sub-
sets of CD4 T cells. In samples from treated and untreated HIV-infected pa-
tients, effector memory CD4 T cells were the main cell population supporting
HIV RNA transcription. The number of cells expressing HIV correlated with the
plasma viral load, intracellular HIV RNA, and proviral DNA quantified by conven-
tional methods and inversely correlated with the CD4 T cell count and the
CD4/CD8 ratio. We also found that after ex vivo infection of unstimulated PBMCs,
HIV-infected T cells upregulated the expression of CD32. In addition, this new
methodology detected increased numbers of primary cells expressing viral tran-
scripts and proteins after ex vivo viral reactivation with latency reversal agents.
This RNA FISH-flow technique allows the identification of the specific cell sub-
populations that support viral transcription in HIV-1-infected individuals and has
the potential to provide important information on the mechanisms of viral
pathogenesis, HIV persistence, and viral reactivation.
IMPORTANCE Persons infected with HIV-1 contain several cellular viral reservoirs
that preclude the complete eradication of the viral infection. Using a novel method-
ology, we identified effector memory CD4 T cells, immune cells preferentially lo-
cated in inflamed tissues with potent activity against pathogens, as the main cells
encompassing the transcriptionally active HIV-1 reservoir in patients on antiretroviral
therapy. Importantly, the identification of such cells provides us with an important
target for new therapies designed to target the hidden virus and thus to eliminate
the virus from the human body. In addition, because of its ability to identify cells
forming part of the viral reservoir, the assay used in this study represents an impor-
tant new tool in the field of HIV pathogenesis and viral persistence.
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HIV-1 infects mainly CD4 T cells and is able to establish viral latency extremelysoon after the initial viral infection (1, 2). Administration of antiretroviral therapy
(ART) efficiently decreases the plasma viral load in the plasma of HIV-infected patients
but does not fully eliminate HIV-1 (3). The presence of latently infected cells that are
able to reinitiate new rounds of viral replication after ART withdrawal (4–6) and the
existence of low-level ongoing viral replication (7), most likely in tissue reservoirs (8–10),
represent the main obstacles to the complete eradication of HIV-1 from the human
body.
The identification of a biomarker that exclusively identifies latently infected cells in
HIV-infected patients remains a challenge. Truly latently infected cells have an inte-
grated copy of HIV inserted within the cell genome and do not produce viral RNA
transcripts and proteins; thus, infected cells harboring latent HIV can barely be distin-
guished from their uninfected counterparts. A new study has recently identified a
potential cell marker for latently infected cells; CD32a was found to be upregulated in
the latent portion of HIV-infected cells in approximately 50% of all reservoir cells (11).
The proportion of latently infected cells able to produce replication-competent virus
is very small; conservative measures using the gold standard quantitative viral out-
growth assay (qVOA) estimate that the fraction of this latent reservoir is about one
infected cell in a million resting CD4 T cells in ART-treated individuals (12, 13). The
characterization of this specific viral reservoir has been hampered for years because of
the extremely low percentage of latently infected cells. Detection of viral nucleic acids
by PCR-based methods is an alternative approximation to identify HIV reservoir cells
(14). Quantification of viral DNA is being used in current cure-related clinical trials as a
marker of therapy effectiveness (15, 16). The total HIV DNA value correlates well with
the qVOA assay and the integrated forms of HIV (17–19). In addition, the total HIV-1
DNA inversely correlates with the time to viral rebound after therapy interruption in
patients who are treated early after infection (20, 21). Viral DNA quantification has been
used to identify the cell composition of the HIV reservoir after the specific isolation of
populations of interest; for instance, central memory, transitional memory, effector
memory, stem cell memory, and follicular CD4 T cells have been identified as the main
cell subsets supporting HIV persistence in patients on ART (22–25). However, a signif-
icant disadvantage of using HIV DNA as a surrogate marker of viral reservoir cells is that
most of the viral DNA is defective and consequently will never produce fully replicative
viral particles (13). Another significant disadvantage of using HIV DNA detection to
study the cell composition of the HIV reservoir is the requirement of previous cell
isolation, making difficult the identification of reservoir cell subsets that represent a
small portion of the total pool of infected cells.
Cells expressing HIV RNA encompass a subset of the total viral reservoir that
contains cells actively transcribing HIV. This specific reservoir has been defined by
Pasternak et al. as the “active viral reservoir” (26). Importantly, a fraction of resting CD4
T cells are capable of expressing HIV RNA without the concomitant production of viral
particles in both ART-treated and untreated HIV-infected patients (27–29). Cell-
associated HIV RNA quantification strongly correlated with disease progression and
inversely correlated with CD4 T cell counts in untreated viremic patients (30–33).
Indeed, unlike plasma viremia, intracellular HIV RNA levels significantly increase over
time during untreated infection (31), and levels of intracellular HIV RNA have been
associated with virological failure in patients on ART (26). The identification of such
infected cells in both treated and untreated HIV-infected persons will provide impor-
tant information regarding the characterization of cells with transcriptionally active HIV,
redirecting the current efforts in the design of new therapies targeting this active viral
reservoir. In addition, as HIV infection frequencies and HIV transcription levels might
differ by cell type and anatomic location (34), the identification of such infected cells
will allow us to determine the specific contribution of HIV to the cellular processes and
functions of this active viral reservoir at different anatomical sites and possible cellular
sources of residual plasma viremia and the release of viral particles after viral reacti-
vation.
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In this study, we have validated a novel RNA fluorescence in situ hybridization-flow
cytometry (FISH-flow) technique that detects intracellular HIV RNA molecules at the
single-cell level in 15 million primary unfractionated peripheral blood mononuclear
cells (PBMCs) from HIV-infected individuals. Using this novel assay, we have character-
ized the cells expressing HIV RNA after ex vivo HIV infection of unstimulated PBMCs, in
primary PBMC samples from ART-treated and untreated HIV-infected patients, and after
ex vivo viral reactivation of primary CD4 T cells. We found that in samples from
HIV-infected patients, the proportion of cells carrying viral transcripts correlated very
well with plasma viral loads and intracellular levels of HIV RNA measured by conven-
tional methods and inversely correlated with the absolute numbers and percentages of
CD4 T cells and CD4/CD8 ratios. The majority of cells supporting HIV transcription had
an effector memory CD4 T cell phenotype. Moreover, we observed that after ex vivo
infection of unstimulated PBMCs, HIV-infected T cells upregulated the expression of the
newly identified marker of latently infected cells CD32. In addition, using this novel RNA
FISH-flow assay, we detected reactivation of HIV from primary CD4 T cell samples from
patients with undetectable plasma viral loads after ex vivo exposure to an activating
stimulus. This investigation characterized the cellular sources of active viral reservoirs
and identified effector memory CD4 T cells as the main subset expressing intracellular
HIV RNA in both untreated and treated HIV-infected individuals. In addition, it provides
a useful tool to evaluate the effectiveness of different latency reversal agents (LRAs) in
different cell subpopulations.
RESULTS
Detection of HIV expression and viral protein production after ex vivo infection
of unstimulated PBMCs. A high-sensitivity target-specific set of 50 individual probes
targeting the HIV RNA Gag-Pol sequence (bases 1165 to 4402 of the HXB2 consensus
genome) was used for HIV RNA detection by the RNA FISH-flow method (Human
PrimeFlow RNA Assay; eBioscience). We chose the Gag-Pol region of HIV-1 because it
detects unspliced forms of viral transcripts. Importantly, cells containing unspliced HIV
RNA decay very slowly after ART initiation and positive cells are successfully observed
in patients on ART (35, 36).
To initially investigate the ability of the new RNA FISH-flow assay to detect HIV
expression, unstimulated PBMCs from healthy donors were infected ex vivo. We ob-
served consistently robust HIV RNA expression (~1% of all cells) in T cells in all ex
vivo-infected cells from HIV-negative donors (Fig. 1A and B). Approximately 40% of
these HIV RNA-expressing cells concomitantly expressed the viral Gag p24 protein and
downregulated the CD4 surface marker, whereas HIV RNA-expressing cells lacking Gag
p24 protein production had high CD4 expression. Thus, a majority (~60%) of the
HIV-transcribing cells did not downregulate the CD4 cell receptor (Fig. 1A). Using this
technique, we were able to distinguish two subpopulations of HIV-expressing cells with
high and low RNA transcript levels (Fig. 1B). Cells expressing low levels of HIV tran-
scription were not able to produce detectable viral proteins (~30% of all HIV-expressing
cells). Therefore, high production of viral transcripts was needed for concomitant
detection of the p24 viral protein and downregulation of the CD4 cell surface marker.
Additionally, we investigated the expression of the newly discovered marker of latently
infected cells, CD32, by using our system of ex vivo infection of unstimulated PBMCs.
We observed that HIV-infected T cells expressing viral RNA and the Gag p24 protein
upregulated CD32 expression (~2-fold increase), while the increase in the expression of
CD32 was less intense in cells expressing only viral RNA (~1.5-fold increase). A slight
increase in the proportion of cells expressing CD32 was also observed upon cell
infection (~10% of all infected cells). The CD32 expression level, however, was consid-
ered low compared to that of non-T cells (Fig. 1C). We also observed the expression of
HIV RNA transcripts and viral Gag p24 protein in non-T-cell populations (see Fig. S1A
and B in the supplemental material). In contrast to infected T cells, most of the infected
non-T cells had simultaneous expression of HIV RNA, Gag p24, and the CD4 receptor
(~1%) (Fig. S1B). More phenotypic experiments are certain to further delineate the
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specific non-T-cell subpopulations supporting HIV replication or viral capture after the
ex vivo infection of primary cells.
Next, we investigated the linearity of the assay. Latently infected J-Lat cells with
detectable basal HIV expression (clone 9.2) were spiked with the noninfected lymphoid
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FIG 1 Detection of HIV transcripts and the viral Gag p24 protein in ex vivo-infected samples by the RNA FISH-flow assay.
Unfractionated and unstimulated PBMCs from healthy donors were infected ex vivo with exogenous HIV strain NL4.3.
Five days after the initial infection, cells were subjected to the RNA FISH-flow protocol. (A) The graphs on the left are
representative flow cytometry plots of HIV transcript detection and CD4 downregulation in Gag p24 T cells. The graphs
on the right show the data summary of CD4 downregulation and the MFI (mean fluorescence intensity) of CD4 expression
in cells expressing HIV RNA with and without production of the viral Gag p24 protein. (B) Left, representative flow
cytometry plot of the dual staining of T cells for HIV RNA and Gag p24 protein. The graph on the right summaries the
percentages of infection of the different combinations of cells costained for detection of HIV RNA and the viral Gag p24
protein in three different infected HIV-negative donors. (C) Left, representative flow cytometry plot of CD32 and HLA-DR
coexpression in HIV-infected cells. Infected cells expressing only HIV RNA (red) or expressing viral RNA and Gag p24 protein
(blue) are overlaid on the whole live-cell population (gray). The graph in the center shows the MFI of CD32 expression in
cells expressing only viral RNA, cells expressing HIV RNA and p24, and uninfected T cells. The graph on the right shows
the percentages of infected cells expressing CD32 and the HLA-DR markers.
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subjected to the RNA FISH-flow protocol. HIV RNA expression determined by the
experimental curve showed robust consistency with the predicted curve at all of the
dilutions tested (down to 50 positive events per million cells) (Fig. S2A). Similar results
were observed when the linearity assay was performed with expanded infected cells
from HIV-infected individuals (Fig. S2B).
Overall, these experiments demonstrated that with a high-sensitivity set of probes
against the Gag-Pol HIV RNA sequence, the RNA FISH-flow assay is a valid method for
detection of HIV RNA expression and viral production after the ex vivo infection of
unstimulated PBMCs.
Detection of CD4 T cells expressing viral transcripts in samples from HIV-
infected patients. Once the assay was validated with ex vivo HIV-infected PBMCs, we
determined the percentage of HIV-expressing cells in primary samples from HIV-
infected individuals. We observed that samples from HIV-negative donors had a
background signal in the HIV RNA detection channel, and this unspecific staining varied
between experiments. For this reason, every independent experiment included at least
one uninfected donor to normalize the percentage of HIV-expressing cells. Fig-
ure S3 shows the raw HIV RNA expression data for additional HIV-infected patients with
different plasma viral loads. Normalization of the data was carried out by subtracting
the percentage of positive cells in the HIV RNA detection channel of the negative
control from the percentage of positive cells measured in each population. After data
normalization, the assay was highly reproducible between different experiments
(Fig. S4A). To test the specificity and background signal of the highly sensitive set of
probes used in this assay, we detected HIV RNA by confocal microscopy in a lymph
node tissue sample from an acutely HIV-infected patient (patient 41; Table S1). Fig-
ure S4B shows the clear detection of HIV transcripts in tissue from an infected patient.
Specifically, we observed two HIV RNA expression patterns, highly positive cells corre-
sponding to HIV RNA-expressing cells and small punctate structures compatible with
the capture of HIV virions by follicular dendritic cells as previously documented (37). Of
note, HIV RNA staining was not observed in the lymph node of the HIV-uninfected
control.
We next determined the percentages of HIV RNA-expressing cells in unstimulated
and unfractionated PBMC samples from patients with chronic untreated HIV infection
and patients on ART (20 copies/ml) compared to uninfected (HIV) donors (patient
characteristics are shown in Table S1). Representative flow cytometry strategy and raw
data from different samples are shown in Fig. 2A and S3. When the percentage of CD4
T cells expressing HIV RNA in 15 million PBMCs was analyzed, untreated HIV-infected
patients showed statistically significantly larger proportions of cells transcribing HIV
than did treated patients or healthy controls (median values of 0.0165 for untreated
patients and 0.001 for treated patients) (Fig. 2B). Therefore, the frequency of cells
transcribing HIV RNA from untreated patients was estimated at 165 per million CD4
T cells, while in ART-treated individuals, we observed a frequency of 10 RNA-
transcribing cells per million CD4 T cells. These values are in agreement with previous
reports (36). When we stratified the samples according to the patients’ plasma viral
loads, we observed that more actively transcribing cells were consistently better
detected in samples with high plasma viral loads. We were able to detect HIV transcripts
in two out of six samples from treated aviremic HIV-infected individuals (Fig. 2C). For
instance, the normalized values of HIV RNA-expressing cells showed a strong positive
correlation with plasma viral loads (r  0.823, P  0.0001) (Fig. 2D) and negatively
correlated with absolute CD4 T cell counts (r  0.723, P  0.0001), percentages of
CD4 T cells in the original samples (r  0.686, P  0.0004), and CD4/CD8 ratios (r 
0.729, P  0.002) (Fig. 2E to G). When we correlated the percentage of positive cells
expressing HIV RNA with viral reservoirs markers, we observed a positive correlation
with total HIV DNA (r  0.672, P  0.039) and intracellular levels of HIV RNA measured
by conventional quantitative PCR (qPCR) (r  0.721, P  0.023) (Fig. S5A and B). The
median frequency of HIV RNA-expressing cells obtained with the RNA flow/FISH assay
was 80 events per million CD4 T cells, compared to 12,804 molecules for total HIV DNA
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FIG 2 Detection of CD4 T cells expressing HIV RNA transcripts in primary samples from HIV-infected patients. Fifteen million PBMCs from healthy
donors and HIV-1-infected patients were thawed and subjected to the RNA FISH-flow protocol for viral transcript detection without any previous
cell stimulation. (A) Lymphocytes were gated by using the forward and side scatter areas (FSC and SSC, respectively), and the debris was excluded
from the analysis. Cell doublets then were removed from the analysis (FSC-A versus FSC-H, followed by SSC-A versus SSC-H), and live cells were
(Continued on next page)
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and 79,871 molecules for intracellular levels of HIV RNA per million CD4 T cells
measured by qPCR (Fig. S5C). In addition, when we performed the qVOA assay with
samples from a separate cohort of aviremic individuals, we did not observe any
correlation between the number of infectious units per million CD4 T cells and the
frequency of memory CD4 T cells expressing HIV RNA obtained with the RNA
flow/FISH assay (Fig. S5D). Overall, the RNA flow/FISH method measured approximately
3-log-fold fewer positive events than the conventional qPCR method. This difference is
due to the fact that the two techniques measure different outcomes; the RNA flow/FISH
method measures the percentage of HIV RNA-expressing cells, and detection of a
positive event requires several RNA molecules per cell. On the contrary, the conven-
tional qPCR method quantifies the number of RNA or DNA molecules in the whole
population of CD4 T cells containing both HIV-infected and uninfected cells. In this
regard, confocal microscopy images of cells transcribing HIV showed numerous positive
dots corresponding to HIV RNA molecules per individual cell (Fig. 2H). Additionally, in
some primary PBMC samples from HIV-infected patients, we costained HIV RNA and the
viral Gag p24 protein. Dual positive cell events were absent or very rarely detected in
any population analyzed (data not shown). The assay of insufficient cell numbers might
explain the failure to detect infected cells harboring both viral markers. Overall, this
novel assay detects actively HIV RNA-transcribing cells in primary samples from infected
individuals, and importantly, levels of cells expressing HIV RNA correlate very well with
different markers of disease progression and intracellular levels of HIV RNA measured
by conventional qPCR.
Identification of CD4 T cell subpopulations expressing HIV-1 RNA transcripts
after ex vivo infection of unstimulated PBMCs. We then assessed the presence of HIV
RNA transcripts in different CD4 T cell subsets after ex vivo infection of unstimulated
and unfractionated PBMCs from healthy donors. Cells were first infected with an
exogenous virus and then stained with antibodies specific for the markers CD3, CD4,
CD45RO, and CCR7 to identify different subpopulations of CD4 T cells. The percent-
ages of HIV RNA-positive cells within the naive (TNA), central memory (TCM), effector
memory (TEM), and terminally differentiated (TTD) CD4 T cell subsets of a representa-
tive ex vivo infection experiment are shown in Fig. 3A. The expression of HIV RNA
transcripts was observed mainly in T memory cells (~0.2% of the total cell population)
(Fig. 3A). Specifically, the majority of cells supporting HIV transcription had a TEM CD4
T cell phenotype and represented 50% of all infected cells (Fig. 3B). The percentage
of TEM cells expressing HIV RNA was higher than in the whole T cell (TCD3) population
(median proportion of positive cells of 0.35 for TEM cells and 0.24 for CD3 T cells)
(Fig. 3B), indicating an enrichment of the subpopulation that supports most active
transcription of HIV (1.38-fold enrichment in TEM cells compared to TCD3 cells). More-
over, infected cell subpopulations only partially downregulated the CD4 cell receptor
upon infection, with the TEM subset being the subpopulation sustaining greater down-
regulation of the CD4 marker (~40% of all TEM-infected cells) (Fig. 3C).
Phenotypic characterization of CD4 T cells expressing HIV-1 RNA transcripts
in primary samples from HIV-infected patients. After the successful identification of
FIG 2 Legend (Continued)
selected by live/dead staining. HIV RNA expression was identified in viable CD4 T cells. Shown are representative flow cytometry plots of HIV
RNA detection in CD4 T cells from a uninfected person (HIV), an ART-treated patient (plasma viral load [VL]  20 copies [cop]/ml;), and
untreated (UNT) patients with different plasma VLs. (B) Summary data of normalized HIV RNA frequency in CD4 T cells in uninfected controls
(HIV; n  6), patients treated with ART (plasma VL of 20 copies/ml; n  6), and untreated patients (n  16). (C) Frequency of HIV RNA detection
stratified by plasma VLs. (D) Correlation of HIV RNA cells and plasma VLs. (E) Correlation of percent HIV RNA cells and absolute numbers of
CD4 T cells in blood. (F) Correlation of percent HIV RNA cells and percent CD4 T cells determined by flow cytometry. (G) Correlation of percent
HIV RNA cells and the CD4/CD8 ratio. (H) Representative micrographs obtained by confocal microscopy of cells from an HIV-negative donor (left)
and an untreated HIV-infected patient (right) after the RNA FISH-flow protocol. Staining of HIV RNA transcripts is red. All HIV RNA percentages
were normalized to those of uninfected donors (obtained by background subtraction) for each independent experiment. White symbols
correspond to values below the limit of detection. In panels D to G, values for untreated patients are represented by gray symbols and values
for treated patients are represented by green symbols. *, P  0.05; **, P  0.01 (Mann-Whitney test). Spearman’s nonparametric correlation
coefficients and associated P values are shown. Data for patients 1 to 6 and 25 to 40 are shown in panels B to F; data for patients 1 to 6, 28 to
33, and 36 to 39 are shown in panel G; and data for patient 26 are shown in panel H (Table S1).
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the CD4 T cell subpopulations transcribing HIV in ex vivo-infected samples, we sought
to phenotypically characterize the subsets of CD4 T cells that support HIV transcrip-
tion in vivo. Fifteen million unfractionated and unstimulated PBMCs from untreated
HIV-infected patients were subjected to the RNA FISH-flow assay to determine the
frequency of HIV RNA-expressing cells. A representative gating strategy used to identify
T cell subsets in an HIV-infected patient is shown in Fig. S6A. We observed greater
proportions of HIV-transcribing cells in all of the subsets assayed than in uninfected
controls, except naive T cells (median values: TNA, 0; TCM, 0.02; TEM, 0.095; TTD, 0.014)
(Fig. 4A). Consistent with the ex vivo infection experiments, the TEM subset was
dominant among the HIV RNA-expressing cells and the proportion of cells expressing
HIV was greater in TEM cells than in all other CD4 T cell subsets (fold increases in TEM
versus other subsets: 124.7 for TNA, 24.8 for TCM, 108.44 for TTD) (Fig. 4B). In addition, HIV
RNA-expressing cells were detected significantly more often within the TEM subset in
samples from aviremic treated HIV-infected patients than in uninfected control samples
(Fig. 4C). Moreover, the percentage of TEM cells expressing viral transcripts was also
higher than that of the other assayed CD4 T cell subsets. We next assessed the
correlation of HIV RNA-expressing cells in the different T cell subsets by using plasma
viral loads and CD4 T cell counts as progression markers. There was a positive
correlation between the plasma viral loads and the percentages of TCM and TEM HIV
RNA-expressing cells, although a more robust correlation was observed for TEM cells
(r  0.7887, P  0.0001) (Fig. 4E). In contrast, we observed a strong inverse correlation
between HIV-expressing TEM cell and CD4 T cell counts (r  0.652, P  0.0007)
(Fig. 4D), similar to what was observed in the entire CD4 T cell compartment (Fig. 2D).
Additionally, after the identification of CD32 as a marker of latently infected cells (11),
we wanted to investigate if cells expressing HIV in samples from aviremic patients were
also expressing the CD32 marker. We observed that cells expressing the CD32 receptor
represented only a small proportion of the total CD4 T cells (median, 0.063; inter-
quartile range, 0.060 to 0.104). Only one of the patients analyzed contained HIV
RNA-expressing cells in this population of cells (Fig. 4F). Taken together, these results
indicate that we successfully detected different subpopulations of cells expressing HIV
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FIG 3 Detection of HIV RNA transcripts in different subsets of CD4 T cells after ex vivo infection of
PBMCs. Unfractionated and unstimulated PBMCs from healthy donors were infected ex vivo with
exogenous HIV. Cells were subjected to the RNA FISH-flow protocol 5 days after infection. (A) Repre-
sentative flow cytometry plots of HIV RNA-expressing cells in different subsets of CD4 T cells (TNA, TCM,
TEM, and TTD). (B) Quantification of HIV RNA cells in the different CD4 T cell subsets of three different
infected HIV-negative donors. (C) Percentages of HIV-expressing TEM and TCM cells that downregulate the
CD4 receptor upon infection.
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T cell subset was largely responsible for the production of HIV RNA in CD4 T cells in
both treated and untreated HIV-infected patients.
Detection of viral reactivation in primary CD4 T cells from ART-treated
HIV-infected patients. Finally, we assessed the ability of this assay to detect HIV RNA
transcripts and the Gag p24 viral protein from previously isolated CD4 T cells after ex
vivo viral reactivation. We evaluated primary samples from treated aviremic infected
patients and assessed the capacity of a strong non-HIV-specific activating stimulus
(phorbol 12-myristate 13-acetate [PMA]–ionomycin [Iono]) and romidepsin, a histone
deacetylase inhibitor, to induce the transcription and translation of HIV. A representa-
tive flow cytometry plot is shown is Fig. 5A. Overall, we observed an increase in the
percentage of cells expressing HIV RNA upon cell activation with PMA-Iono compared
with the corresponding control (5.53-fold change), and upon cell activation with
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FIG 4 Identification of CD4 T cell subsets supporting HIV expression in primary samples from HIV-infected patients. Fifteen million unfractionated and
unstimulated PBMCs from HIV-infected patients were subjected to the RNA FISH-flow protocol for viral transcript detection in the different CD4 T cell subsets
(TNA, TCM, TEM, and TTD). (A) Frequencies of HIV RNA-expressing cells in different CD4 T cell subpopulations of untreated patients (n  13). The frequency of
viral transcription in each subpopulation was compared with that of the HIV-negative control by using the Mann-Whitney test. (B) Paired comparison of HIV
RNA cells in CD4 T cell subsets of untreated patients (n  13). The statistical values shown were obtained with the Wilcoxon signed-rank test with corrected
P values for multiple comparisons. (C) Frequency of HIV RNA-expressing cells in CD4 T cell subsets of treated patients with undetectable plasma viral loads
(n  10). (D) Spearman correlation of HIV RNA frequency in the different CD4 T cell subpopulations and the absolute CD4 T cell counts (n  23). (E) Spearman
correlation between plasma viral loads and the percentages of CD4 T cells expressing HIV RNA in different subsets (n  23). For all correlations, white symbols
represent values below the limit of detection, symbols representing values for untreated patients are in dark colors, and symbols representing values for treated
patients are in pale colors. (F) Frequencies of HIV RNA-expressing cells in CD4 T cells expressing CD32 and HLA-DR. All normalized values were obtained after
subtracting the corresponding background signal observed in the HIV-negative control. *, P  0.05; **, P  0.01. Data for patients 28 to 40 (Table S1) are shown
in panels A and B; those for patients 1 to 6, 10, and 13 to 15 are shown in panel C; those for patients 1 to 6, 10, 13 to 15, and 28 to 40 are shown in panels
D and E; and those for patients 7, 10, 11, 16 to 20, and 24 are shown in panel F.
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romidepsin, four out of four patients showed increasing proportions of HIV RNA-
expressing cells (3.69-fold change) (Fig. 5B and E). The median numbers of RNA-positive
cells per million CD4 T cells before and after viral reactivation were 20 and 145 for
PMA-Iono and 6 and 58 for romidepsin, respectively. Moreover, the expression of cells
doubly positive for HIV RNA and Gag p24 rose significantly when cells were stimulated








































































































































































































FIG 5 Detection of HIV-1 RNA and Gag p24 protein in primary CD4 T cells from HIV-infected patients
after ex vivo reactivation. CD4 T cells from treated HIV-infected patients were isolated with magnetic
beads. Expression of HIV RNA and the viral Gag p24 protein was detected by the RNA FISH-flow
technique after 13 h of reactivation with PMA-Iono or 24 h of reactivation with romidepsin. (A)
Representative flow cytometry plots of cells from a treated patient before and after viral reactivation with
PMA-Iono. Live cells were identified, and single HIV RNA-expressing cells gated against side scatter (SSC)
are shown on the left. Percentages of HIV RNA cells that were Gag p24 are shown on the right. (B, C)
Comparisons of HIV-1 RNA single cells after viral reactivation with PMA-Iono (B) and HIV-1 RNA Gag
doubly positive cell frequencies before and after viral reactivation (PMA-Iono) (C). (D) Frequencies of
HIV-1 RNA single cells expressing Gag before and after stimulation with PMA-Iono. (E) Comparison of
HIV-1 RNA single cells after viral activation with romidepsin. (F, G) Comparisons of HIV-1 RNA single
cells after viral reactivation with romidepsin (F) and doubly positive cells HIV-1 RNA Gag frequencies
before and after viral reactivation (romidepsin) (G). Cells from nine patients were treated with PMA-Iono
(patients 5 and 7 to 13 are shown in panels B to D), and cells from four patients were treated with
romidepsin (RMD) (patients 7 and 21 to 23 are shown in panels E to G). *, P  0.05 (paired nonparametric
t test). FC, fold change.
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CD4 T cells (Fig. 5C). For romidepsin, we observed positive p24 events in only one
patient (Fig. 5F). Of note, the range of dually positive cells was highly dependent on the
patient. Also, when we analyzed the percentage of cells transcribing HIV RNA that also
translated Gag p24 after stimulation with PMA-Iono, we observed a significant increase
in the numbers of HIV RNA cells concomitantly expressing HIV proteins. However, the
degree of expression was also highly variable between different patients and was
observed only for PMA-Iono (Fig. 5D). For romidepsin, however, this increase was very
modest and was observed in only one patient (Fig. 5G). Thus, this assay could be used
to evaluate the effectiveness of different LRAs in reversing the latent state of the HIV
reservoir in different cell populations.
DISCUSSION
Identification of the HIV-1 cell reservoirs that exist in HIV-infected patients will
significantly advance the design of new targeted therapies aimed at curing HIV. In this
regard, the identification and characterization of active viral reservoirs, defined as
infected cells with transcriptionally active HIV, have been limited by an inability to
isolate the required amount of cells for accurate quantification of viral transcription. In
this investigation, we used a new RNA FISH-flow assay for the identification of HIV-
infected cells that express viral transcripts both after ex vivo infection and in primary
samples from HIV-infected patients. In addition, we used this novel method to assess
viral reactivation in primary CD4 T cells from HIV-infected patients after ex vivo
exposure to an activating stimulus.
Using this novel assay that measures transcriptionally competent HIV-infected cells,
we found that after ex vivo infection of unstimulated PBMCs, HIV transcription was
significantly detected in T cells and production of viral proteins correlated well with the
downregulation of the CD4 cell receptor. This finding is in agreement with previously
published data showing that different viral proteins are responsible for the downregu-
lation of CD4 on the surface of the infected cell (38, 39) and higher levels of HIV RNA
expression are required for productive infection (40, 41). Importantly, we also observed
that non-T cells expressed HIV transcripts and viral proteins and most of these non-T
cells expressed the CD4 receptor. In this investigation, we have not fully identified these
non-T-cell populations harboring both HIV RNA and the Gag p24 protein, although viral
capture by dendritic cells and viral replication in monocytes would be a possible
explanation for the present results (42, 43). More precise phenotypic studies are needed
to fully identify the non-T-cell populations supporting HIV transcription and translation
after ex vivo infection.
Using the RNA flow/FISH protocol, we found that the majority of HIV RNA-positive
cells in primary samples from infected patients were detected in CD4 T cells and we
were not able to observe significant detection of HIV transcripts in the CD4 T cell
population. This result is consistent with previous reports where CD4 T cells were
enriched in unspliced viral transcripts compared to T cells that downregulated the CD4
receptor (44). Moreover, in treated patients, HIV RNA in blood and tissue was highly
concentrated in the CD4 population compared to non-CD4 T cells (45). In addition,
T cells that downregulate the CD4 receptor support the greatest production of viral
particles; thus, higher rates of cell death in this infected population during the exper-
imental protocol might also account for our results (46). In agreement with the lack of
significant detection of HIV RNA in CD4 T cells, we did not detect cells expressing both
viral RNA and the viral Gag p24 protein in samples from HIV-infected patients without
previous cell stimulation. In addition to cell death, the assay of insufficient cell numbers
may explain the lack of detection of dually stained cell populations.
Frequencies of CD4 T cells expressing HIV transcripts in samples from HIV-infected
patients measured by this novel method had a median of 10 positive cells per million
CD4 T cells in aviremic patients and 165 positive cells per million CD4 T cells in
viremic untreated individuals. These data fully agree with previous studies (29, 36).
Importantly, these frequencies correlated very well with different markers of disease
progression such as plasma viral loads, CD4 T cell counts, and CD4/CD8 ratios. Our
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data agree with previously published data showing that intracellular HIV RNA quanti-
fication strongly correlated with disease progression and inversely correlated with
CD4 T cell counts in untreated viremic patients (30–33). Previous reports have shown
that during the chronic phase of infection, intracellular levels of HIV RNA range
between 3- and 4-log magnitudes of molecules per million unfractionated PBMCs (31);
however, after ART initiation, the levels of cell-associated HIV RNA only decline about
1 to 2 logs (47, 48) and positively correlate with the total viral reservoir measured by
total HIV DNA quantification (49). When we performed a direct comparison of the
quantitative values obtained by conventional methods of intracellular viral nucleic
acids and the percentage of positive cells measured by the RNA FISH-flow technique,
we observed a direct significant correlation between the two methods; however, our
novel method quantified 3-log-fold lower values than the RNA molecule levels in CD4
T cells quantified by qPCR and 2-log-fold lower values than the number of DNA
molecules per million CD4 T cells measured by conventional methods. The impossi-
bility of measuring the exact numbers of HIV RNA and DNA molecules in a single cell
by qPCR makes this comparison biased, since detection of positive events by the RNA
FISH-flow technique most likely requires the presence of several HIV RNA molecules, as
we have observed in our micrographs. In this regard, previous reports showed that
productively HIV-infected cells contained ~300 HIV RNA copies per cell (35, 50, 51).
Moreover, the lower sensitivity of the RNA FISH-flow method than the PCR-based
method might also explain part of these differences. When we compared the propor-
tions of memory CD4 T cells expressing HIV RNA calculated by the RNA FISH-flow
assay and the qVOA, we did not observe any correlation. The proportion of viral
RNA-expressing cells not able to produce fully replicative virions might be responsible
for this result. In the same line, intracellular HIV RNA quantification by qPCR has
correlated poorly with qVOA results in previous studies (17, 18).
In treated aviremic patients, the identification of the cellular sources of HIV tran-
scripts is of particular importance since this information will directly identify the specific
cell subpopulations supporting HIV persistence. HIV transcripts can be found in latently
infected cells that do not produce viral particles, in productive infection of new cells, or
in cells reactivated from latency with productive production of viral particles (26). To
date, the precise composition of the cellular subpopulations that support this active
viral reservoir in HIV-infected patients is largely unknown. We identified the effector
memory CD4 T cell subpopulation as the main subset of cells expressing HIV during
both untreated and treated infections. In this regard, the detection of infected cells in
the fraction of PBMCs could be an intrinsic limitation of our study, since central memory
T cells recirculate constitutively between secondary lymphoid organs and blood and
effector memory T cells circulate through blood and home to inflamed tissue (52). Thus,
not all of the cell subsets analyzed in this study are continuously present in peripheral
blood. Of note, identification of effector memory CD4 T cells was carried out by using
the phenotypic markers CD45RO and CCR7, and therefore, this population can also
contain cells with a transitional memory phenotype (53).
In agreement with our data, previous studies identified effector memory cells as the
main subset supporting HIV transcription in both peripheral blood and ileum and
rectum tissue samples from ART-treated patients (45). On the basis of HIV DNA
quantification, TEM cells were also identified as one of the main subsets harboring total
and integrated HIV DNA (22, 23, 25). Follicular helper T cells have been recently
identified as one of the main cell subsets that support the replication, transcription, and
production of HIV-1 (24). Although we did not perform a detailed investigation of that
specific cell subpopulation in this study, we present our method as a promising tool for
the identification of transcriptionally active HIV in cell subpopulations, including follic-
ular helper T cells, from different tissue samples.
A new biomarker of latently infected cells has recently been described. Descours et
al. reported that the immunoglobulin G Fc fragment CD32a was exclusively induced in
quiescent infected cells. Productive infection of stimulated CD4 T cells was not
associated with significant CD32a expression, compared to that in resting CD4 T cells
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(11). Thus, we also explored the expression of CD32 in cells transcribing HIV in vitro and
in vivo by our newly described method. We found that after ex vivo infection of
unstimulated PBMCs, infected cells concomitantly upregulated the expression of CD32
and the activation marker HLA-DR; productively infected cells expressing HIV RNA and
Gag protein upregulated both markers to a greater degree (2-fold increase) than cells
transcribing only HIV RNA (1.5-fold increase). Moreover, the proportion of cells express-
ing CD32 also increased. On the basis of these results, we concluded that productive
HIV infection upregulates the expression of CD32. Levels of CD32 were very modest
compared to those of non-T cells. Of note, with our system, we cannot compare these
levels to those expressed in latently infected cells. The discrepancy between the study
of Descours et al. and our results may be due to the fact that Descours et al. stimulated
their PBMCs before productive infection, while we performed infections without any
previous cell stimulation. In addition, Descours et al. focused their analysis on the
HLA-DR cell population. Further studies are certain to fully elucidate the role of CD32
in HIV infection and latency.
HIV RNA transcription is a useful tool with which to assess the effect of LRAs in new
therapeutic approximations aimed at curing HIV. LRAs are being used in clinical trials
to reactivate HIV from its dormant state. However, clinical studies have shown only a
modest reduction of the latent HIV reservoir after LRA administration (15, 16, 54). As
LRAs may not work equally in all infected cell subpopulations, new methods to assess
the effectiveness of LRAs in vitro are highly desirable. Previous reports have shown the
ability of the RNA FISH-flow assay to detect viral reactivation in primary samples and
cell lines (55, 56). Here, we used our method to detect viral reactivation in primary
infected CD4 T cells after the ex vivo administration of an activating stimulus. In
samples from treated HIV-infected patients, romidepsin significantly increased the
percentage of cells expressing HIV RNA; however, we were not able to detect a
significant production of viral proteins. This result is consistent with previously reported
studies where romidepsin alone failed to induce robust production of viral particles (57,
58). However, upon cell stimulation with PMA-Iono, significant percentages of cells
expressing HIV and viral proteins were successfully detected. HIV RNA expression
increased very modestly upon viral reactivation. The fact that we focused our analysis
on cells with high expression of HIV RNA to avoid an increased background might
account for this result. Importantly, and in agreement with our data, previous reports
have shown that the number of unspliced HIV RNA molecules per cell during different
stages of viral production varies only slightly; transcription of unspliced HIV RNA per cell
was unaffected by treatment status and ongoing viral replication (35, 36). Using this
method, we estimated that the median size of the inducible reservoir, defined as cells
able to express viral RNA and the Gag p24 protein upon cell activation, was six per
million CD4 T cells. This number is higher than previously reported frequencies of
latently infected cells measured by the gold standard qVOA assay (12, 13). However, we
are not able to exclusively detect the fraction of cells with replication-competent virus.
Our estimated size of the inducible reservoir is, however, smaller than that predicted by
the tat/rev-induced limiting-dilution assay, which accounts for the fraction of cells with
transcriptionally active HIV-1 (29). How our novel method correlates with previously
reported assays designed to measure the size of the latent reservoir deserves a more
detailed investigation; in-depth comparison with the same samples will be indispens-
able to fully estimate the ability of the RNA flow/FISH assay to accurately measure the
size of the HIV-1 reservoir.
An assay that detects translation-competent HIV-infected cells on the basis of the
same technology has been recently reported (56). Baxter et al. simultaneously detected
both HIV RNA and the viral Gag p24 protein in primary HIV-infected samples. However,
a very high background signal level in the HIV RNA channel precluded the use of the
assay to identify the fraction of transcriptionally competent HIV-infected cells. In our
study, however, the use of a high-sensitivity set of 50 probes that recognize the Gag-Pol
sequence of the HXB2 consensus genome with a minimized background signal and
subtraction of the nonspecific background from the quantification of HIV RNA-
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expressing cells allowed us, for the first time, to detect significant differences in the
levels of HIV RNA-expressing cells in different cohorts of HIV-infected patients.
Overall, in this study we have found that effector memory CD4 T cells are an
important niche for HIV transcription in vivo. The identification of transcriptionally
active HIV-infected cells will provide important information on the specific cellular and
anatomical sources of residual viremia, the contribution of HIV to viral pathogenesis,
and the specific cellular reservoirs that persist in ART-treated individuals. In addition,
this novel method detects viral reactivation in primary CD4 T samples, providing a
useful tool with which to evaluate the effectiveness of different LRAs in different cell
subpopulations.
MATERIALS AND METHODS
Ethics statement. PBMCs from HIV-1-infected patients were obtained from the HIV unit of the
Hospital Universitari Vall d’Hebron in Barcelona, Spain. Written informed consent was provided by all of
the patients who participated in this study, and the protocols used were approved by the Comité d’Ètica
d’Investigació Clínica (Institutional Review Board numbers 39-2016 and 196-2015) of the Hospital
Universitari Vall d’Hebron, Barcelona, Spain. Samples were obtained only from adults, who all provided
written informed consent, and the samples were prospectively collected and cryopreserved in the
Biobanc (register number C.0003590). All samples received were totally anonymous and untraceable. The
J-Lat cell line and the T-lymphoblastoid MOLT-4 CCR5 cell line were obtained from the NIH AIDS
Reagent Program.
Study samples. Samples from HIV-1-infected patients with CD4 T cell counts of 100/mm3 in the
HIV unit of the Hospital Universitari Vall d’Hebron in Barcelona, Spain, were included in this study.
Information on plasma viral loads, CD4 T cell counts, and time on ART for treated patients is
summarized in Table S1.
Cells and virus. PBMCs were obtained from HIV-1-infected patients by Ficoll-Paque density gradient
centrifugation and cryopreserved in liquid nitrogen. PBMCs from healthy donors were obtained anon-
ymously from the BST (Banc de Sang I Teixits, Barcelona, Spain) and isolated as described above.
The human latently infected cell line J-Lat (clone 9.2) was obtained through the NIH AIDS Reagent
Program from Eric Verdin (59); grown in RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS; Gibco, Life Technologies, Inc.), 100 U/ml penicillin, and 100 g/ml streptomycin (Life Technologies,
Inc.); and maintained at 37°C in a 5% CO2 incubator. The T-lymphoblastoid MOLT-4 CCR5 cell line
(obtained through the NIH AIDS Reagent Program from Masanori Baba, Hiroshi Miyake, and Yuji Iizawa)
(60) was cultured in R10 (RPMI medium with 10% FBS) containing 1 mg/ml G-418.
The plasmid encoding HIV-1 strain NL4.3 (pNL4.3) was obtained through the NIH AIDS Reagent
Program from Malcom Martin. Viral stocks were generated by transfection of 293T cells with pNL4.3, and
the resulting viral particles were titrated in TZMbl cells by enzyme luminescence assay (britelite plus kit;
PerkinElmer) as described previously (61).
Ex vivo infection of unstimulated PBMCs. PBMCs from healthy donors were quickly thawed and
incubated overnight in R10 with 100 g/ml streptomycin, 100 U/ml penicillin, and 40 U/ml interleukin-2
(IL-2). On the next day, PBMCs were infected (350,000 50% tissue culture infective doses/million cells)
with the NL4.3 viral strain for 4 h at 37°C and 5% CO2. Following the initial infection, the cells were
thoroughly washed and cultured in six-well plates in R10 plus 100 U/ml IL-2 for an additional 5 days to
expand the viral infection. The cells were then subjected to the RNA FISH-flow protocol as described
below.
Detection of single cells expressing HIV-1 RNA transcripts by the RNA FISH-flow assay. The RNA
FISH-flow assay for detection of HIV transcripts was performed in accordance with the manufacturer’s
instructions (Human PrimeFlow RNA Assay; EBioscience), with some modifications. Briefly, 15 million
PBMCs were stained with antibodies to cell surface markers (20 min at room temperature [RT]; CCR7,
30 min at 37°C) and violet viability dye (20 min at RT). Cells were then fixed, permeabilized, and
intracellularly stained for detection of the viral p24 protein when required (60 min at 4°C). After an
additional fixation step, cells were ready for 3 h of hybridization at 40  1°C with a high-sensitivity
target-specific set of 50 probes spanning the whole Gag-Pol HIV mRNA sequence (bases 1165 to 4402 of
the HXB2 consensus genome). The cells were then subjected to different amplification steps (sequential
2-h incubations at 40°C with the preamplification and amplification mixtures). Finally, multiple label
probes were hybridized with the specific amplifiers (1 h at 40°C). Negative controls were included in all
experiments with cells from non-HIV-infected donors. The normalized percentage of HIV RNA expression
was calculated for each subpopulation by subtracting the mean value obtained from the negative
control from the signal obtained with the real sample. All samples were run on an LSR Fortessa four-laser
flow cytometer (Becton, Dickinson).
Antibody panel. To identify the different CD4 T cell subpopulations expressing HIV RNA, PBMCs
were stained for cell surface markers with CD4 (AF700; BD), CD3 (phycoerythrin [PE]-Cy7; BD), CCR7 (PE;
BD), and CD45RO (BV605; BioLegend) antibodies. The CD4 T cell subset phenotypes were identified as
follows: TNA, CD3 CD4 CCR7 CD45RO; TCM, CD3 CD4 CCR7 CD45RO; TEM, CD3 CD4 CCR7
CD45RO; TTD, CD3 CD4 CCR7 CD45RO. For detection of CD32 after ex vivo infection, we used CD4
(AF700; BD), CD3 (PE-Cy5; BD), p24 (PE; Beckman Coulter, Inc.), CD32 (PE-Cy7; BioLegend), and HLA-DR
(fluorescein isothiocyanate; BioLegend) antibodies. For detection of CD32 in samples from HIV-infected
patients, we used CD4 (AF700; BD), CD3 (PE-Cy5; BioLegend), CD45RO (BV605; BioLegend), CD32 (PE-Cy7;
Grau et al. ®
July/August 2017 Volume 8 Issue 4 e00876-17 mbio.asm.org 14
BioLegend), and HLA-DR (PE; BioLegend) antibodies. The expression of HIV RNA transcripts was analyzed
with target-specific AF647-labeled probes, and expression of the viral Gag p24 protein was detected with
a PE-conjugated anti-p24 antibody (clone KC57 RD1; Beckman Coulter, Inc.). Cell viability was determined
with a violet viability dye for flow cytometry (LIVE/DEAD Fixable Violet Dead Cell Stain kit; Invitrogen).
Linearity of the RNA FISH-flow assay. To test the linearity of the assay, latently infected Jurkat (J-Lat
clone 9.2) cells were spiked with the T-lymphoblastoid MOLT-4 CCR5 cell line at four different ratios
(1/3 serial dilutions). Samples were then subjected to the RNA FISH-flow assay. The predictive curve was
determined by the basal expression of green fluorescent protein within the J-Lat cells and the subse-
quent theoretical values of the serial dilutions. The infection rate (experimental curve of percent HIV
RNA cells) was calculated by using the values obtained with the RNA FISH-flow assay. Linear regression
was computed to determine the linearity of the relationship between the predicted and experimental
values of the assay. The linearity of the assay was also measured after expanding the infection of primary
CD4 T cells from HIV-infected patients. We used the same protocol described for the qVOA assay, and
the positive wells were mixed up and diluted into uninfected cells at six different ratios. The predictive
curve was determined by the basal expression of p24 and the subsequent theoretical values of the serial
dilutions.
Ex vivo viral reactivation of primary CD4 T cells. Primary CD4 T lymphocytes from PBMCs of
HIV-infected patients were purified by negative selection in accordance with the instructions provided by
the manufacturer (MagniSort Human CD4 T Cell Enrichment; Affymetrix). Isolated CD4 T cells (purity
routinely 95%) were cultured in complete RPMI medium supplemented with 10% FBS, 100 g/ml
streptomycin, and 100 U/ml penicillin alone or stimulated with PMA (50 ng/ml; Abcam, Inc.) and Iono
(0.5 g/ml, Abcam, Inc.) for 13 h in the presence of raltegravir (1 M) and nevirapine (100 nM) or with
romidepsin (40 nM) for 24 h. Cells were then extensively washed and subjected to the RNA FISH-flow
assay for detection of viral RNA and the viral Gag p24 protein. A minimum of 2 million CD4 T cells were
used per condition.
Confocal microscopy of cells following the RNA FISH-flow assay. Following the RNA FISH-flow
assay protocol, samples were fixed for 30 min at 4°C with 4% PFA, washed with phosphate-buffered
saline, and smeared onto a microscope slide. Preparations were finally mounted with Fluoromount G
(EBioscience). Preparations were imaged with an Olympus FV1000 Spectral Deconvolution Confocal
Microscope. ImageJ software was used for all image compositions.
HIV-1 RNA in situ hybridization in lymph nodes. To evaluate the specificity of the target-specific
high-sensitivity probes that detect HIV transcripts in primary samples from an HIV-infected patient
(probes for bases 1165 to 4402 of the HXB2 consensus genome), we used the ultrasensitive ViewRNA ISH
Tissue 2-Plex Assay kit (eBioscience), which detects RNA molecules in tissue samples. A lymph node
sample from an acutely HIV-infected patient (patient 41, Table S1) was fixed and embedded in paraffin.
Sections (6 m each) were mounted on Superfrost Plus microscope slides (Fisher Scientific). Before the
assay was performed, samples were heated for 1 h at 60°C, dewaxed in xylene, and then placed in 100%
ethanol before being air dried. The ViewRNA protocol was performed in accordance with the manufac-
turer’s instructions. Briefly, heat-induced epitope retrieval was performed by boiling sections in pretreat-
ment solution for 10 min, and additional protease digestion was performed at 40°C for 20 min.
Hybridization was carried out by slide incubation with target probes for 2 h at 40°C. After that, samples
were stored overnight in storage buffer. On the next day, signal amplification was achieved by sequential
slide incubation with PreAmplifier Mix and Amplifier Mix for 25 and 15 min at 40°C, respectively. Samples
were then incubated with the appropriated label probe and substrate. Finally, slides were counterstained
with 4’,6-diamidino-2-phenylindole (DAPI), air dried, and mounted with Fluoromount G. Samples were
imaged on an Olympus FV1000 Spectral Deconvolution Confocal Microscope with a 10 phase objective
in sequential mode to separately capture the fluorescence from the different fluorochromes at an image
resolution of 800 by 800 pixels.
HIV DNA and intracellular HIV RNA quantification by qPCR. CD4 T cells were isolated by
negative selection as mentioned above. A total of 1.5 million cells were subjected to RNA extraction by
the total RNA extraction protocol (mirVana; Ambion). RNA was reverse transcribed with SuperScriptIII
(Invitrogen) in accordance with the instructions provided by the manufacturer, and cDNA was quantified
by qPCR with primers and probes specific for the HIV long terminal repeat-gag region. Copies of HIV RNA
were quantified with an HIV RNA standard, and values were normalized to micrograms of RNA of the
original sample. For HIV DNA quantification, 1 million CD4 T cells were immediately lysed with a
proteinase K-containing lysis buffer. Cell lysates were subjected to total HIV DNA quantification as
previously described (18). The gene for CCR5 was used for cell input normalization.
qVOAs. qVOAs were performed as previously described, with some modifications (18). Briefly, CD4
T cells from HIV-1-infected patients were isolated by negative selection (Affymetrix) and cultured at
50,000/well in R10 supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin.
Subsequently, cells were stimulated with phytohemagglutinin (PHA; 2 g/ml), recombinant IL-2 (100 U/
ml), and irradiated allogeneic PBMCs (50 Gy in a Cs source irradiator for 20 min) obtained from
HIV-negative healthy donors (100,000/well) and cultured in an incubator at 37°C and 5% CO2. After 48 h,
the PHA was completely washed away and MOLT-4 CCR5 cells were added at 10,000/well on day 2 of
culture and again on day 9. The cultures were subjected to the removal of 100 l of just medium on day
6 and 100 l of the cell suspension on day 9 and replenished with fresh complete medium containing
recombinant human IL-2 (100 U/ml). After 12 days, cell supernatant was collected from each well and the
number of wells containing infectious HIV-1 was assessed by incubation of the supernatant with TZM-bl
cells. Luciferase activity was quantified on day 14 by luminescence assay in accordance with the
manufacturer’s instructions (britelite plus kit; PerkinElmer) and is directly proportional to the number of
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infectious virus particles present in the initial inoculum. Latently HIV-1-infected ACH-2 cells were run as
positive controls. Estimated frequencies of cells with replication-competent HIV-1 were calculated by
limiting-dilution analysis as described in reference 62.
Statistical analysis. Statistical analyses were performed with the Prism software, version 5.0 (Graph-
Pad). Comparisons of the frequencies of HIV RNA-expressing cells in infected patients and healthy donors
were performed with the nonparametric Mann-Whitney test. For correlations, Spearman’s correlation
coefficient was calculated. To test the linearity of the assay, a linear regression was performed. A paired
t test (Wilcoxon signed-rank test) was used to compare HIV RNA expression levels in CD4 T cell subsets
with corrected P values for multiple comparisons. A P value of 0.05 was considered significant.
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